Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice
Immunomodulators that remodel the tumor immunosuppressive microenvironment have
been combined with anti–programmed death 1 (α-PD1) or anti–programmed death ligand 1 …
been combined with anti–programmed death 1 (α-PD1) or anti–programmed death ligand 1 …
Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy
Z Xiao, Z Su, S Han, J Huang, L Lin, X Shuai - Science advances, 2020 - science.org
The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-
L1) blockade in cancer immunotherapy is limited because of multiple immune evasion …
L1) blockade in cancer immunotherapy is limited because of multiple immune evasion …
[HTML][HTML] Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
F Ordikhani, M Uehara, V Kasinath, L Dai… - JCI insight, 2018 - ncbi.nlm.nih.gov
Recent studies in cancer research have focused intensely on the antineoplastic effects of
immune checkpoint inhibitors. While the development of these inhibitors has progressed …
immune checkpoint inhibitors. While the development of these inhibitors has progressed …
[HTML][HTML] Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
S Cai, Z Chen, Y Wang, M Wang, J Wu, Y Tong… - Theranostics, 2021 - ncbi.nlm.nih.gov
The binding between the immune checkpoints, programmed cell death ligand 1 (PD-L1) and
programmed cell death 1 (PD-1), compromises T-cell-mediated immune surveillance …
programmed cell death 1 (PD-1), compromises T-cell-mediated immune surveillance …
Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy
Y Cheng, C Wang, H Wang, Z Zhang, X Yang, Y Dong… - BMC medicine, 2022 - Springer
Background The application of combination therapy for cancer treatment is limited due to
poor tumor-specific drug delivery and the abscopal effect. Methods Here, PD-L1-and CD44 …
poor tumor-specific drug delivery and the abscopal effect. Methods Here, PD-L1-and CD44 …
Tumor-targeted self-assembled micelles reducing PD-L1 expression combined with ICIs to enhance chemo-immunotherapy of TNBC
H Zhu, K Ma, R Ruan, C Yang, A Yan, J Li, Q Yu… - Chinese Chemical …, 2024 - Elsevier
Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death ligand 1 (PD-
L1) and programmed death protein 1 (PD-1) had exhibited significant clinical benefits for …
L1) and programmed death protein 1 (PD-1) had exhibited significant clinical benefits for …
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
D Wang, T Wang, H Yu, B Feng, L Zhou, F Zhou… - Science …, 2019 - science.org
Immunological tolerance of tumors is characterized by insufficient infiltration of cytotoxic T
lymphocytes (CTLs) and immunosuppressive microenvironment of tumor. Tumor resistance …
lymphocytes (CTLs) and immunosuppressive microenvironment of tumor. Tumor resistance …
[HTML][HTML] Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with
chemotherapeutic drugs has provided significant clinical advances. However, such …
chemotherapeutic drugs has provided significant clinical advances. However, such …
Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression
C Li, S Qiu, K Jin, X Zheng, X Zhou, D Jin, B Xu, X Jin - Cancer Letters, 2021 - Elsevier
Membrane vesicles, including exosomes and microparticles (MPs), serve to package and
transfer the cellular cargo during inter/extracellular communication, which is of great interest …
transfer the cellular cargo during inter/extracellular communication, which is of great interest …
STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in …
RS Cavalcante, U Ishikawa, ES Silva… - British Journal of …, 2021 - Wiley Online Library
Background and Purpose Inflammation associated with the tumour microenvironment (TME)
is critical for cancer development, and immunotherapeutic strategies modulating the immune …
is critical for cancer development, and immunotherapeutic strategies modulating the immune …
相关搜索
- breast cancer pd l1
- albumin nanoparticle pi3kγ inhibitor
- tumor remission pi3kγ inhibitor
- albumin nanoparticle tumor remission
- paclitaxel in combination pi3kγ inhibitor
- albumin nanoparticle paclitaxel in combination
- albumin nanoparticle breast cancer
- breast cancer pi3kγ inhibitor
- paclitaxel in combination tumor remission
- breast cancer paclitaxel in combination
- breast cancer tumor remission
- breast cancer immune cells
- cancer immunotherapy prodrug nanoparticles
- prodrug nanoparticles pd l1
- engineering nanoparticles tumor microenvironment
- breast cancer associated macrophages